Press Releases

 
Press Releases
Date Title and Summary View
May 12, 2014 MADISON, Wis., May 12, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss first quarter 2014 financial results and provide an update on each of its deve...
PDF
May 5, 2014
Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration
Company Expects to Complete Ongoing Multi-Center Phase II Imaging Trial of I-124-CLR1404 in Patients with Glioblastoma By Year-End
MADISON, Wis., May 5, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that it has received notification from the U.S. Food and Drug Administration (FDA) granting Cellectar's request for orphan drug designat...
PDF
Apr 2, 2014 MADISON, Wis., April 2, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as actin...
PDF
Mar 19, 2014 MADISON, Mar 19, 2014 (GLOBE NEWSWIRE via COMTEX) -- Cellectar Biosciences, Inc. (otcqx:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013 financial results, provide an update on each of its develo...
PDF
Mar 4, 2014 Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-End 2014 MADISON, Wis., March 04, 2014, – Cellectar Biosciences, Inc. (OTCQX: CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient i...
PDF
Feb 11, 2014 Stock to be Quoted Under Ticker Symbol CLRB Beginning February 12, 2014 MADISON, Wis., February 11, 2014, – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents for the detection and treatment of cancer, announced that, effective today, its corporate name wil...
PDF
Feb 10, 2014 MADISON, Wis. (February 10, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents to detect, treat and monitor a broad spectrum of cancers, today announced that Dr. Simon Pedder, acting president and CEO of Novelos, will present at the 16th Annual BIO CEO & Investor Confere...
PDF
Feb 7, 2014 MADISON, Wis. (February 07, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, is pleased to announce that it has closed the previously disclosed non-brokered private placement of two-year, 8% convertible debentures and warrants, raising...
PDF
Feb 6, 2014 Proceeds Enable Initiation of Phase II Trial of 124I-CLR1404 in Glioma in First Quarter 2014 MADISON, Wis. (February 06, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, today announced it has entered into definitive ag...
PDF
Nov 13, 2013 Board Appoints Paul Berns as New Independent Director and Reduces Board from Nine to Five Directors Company to Relocate Executive Offices, Close Newton Office and Centralize Operations in Madison, Wisconsin Company Initiates Key Management Changes to Support New Strategic Initiatives and Transition of Operations to Madison...
PDF
Page: FirstPrevious ...
15
... NextLast